Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan;67(1):91-97.
doi: 10.1007/s10840-023-01578-w. Epub 2023 May 29.

Role of dofetilide in patients with ventricular arrhythmias

Ghanshyam Shantha  1 , Matthew Singleton  2 , Patrick Kozak  3 , George Bodziock  3 , Auras R Atreya  4 , Bharat Narasimhan  5 , Abhishek Deshmukh  6 , Jackson J Liang  7 , Patrick Hranitzky  8 , Patrick Whalen  3 , Prashant Bhave  3
Affiliations

Role of dofetilide in patients with ventricular arrhythmias

Ghanshyam Shantha et al. J Interv Card Electrophysiol. 2024 Jan.

Abstract

Background or purpose: To assess effectiveness of dofetilide in reducing the burden of ventricular arrhythmias (VAs).

Background: Prior small sample studies show that dofetilide has benefit in reducing VA. However, large sample investigations with long-term follow-up are lacking.

Methods: Two hundred seventeen consecutive patients admitted between January 2015 and December 2021 for dofetilide initiation for control of VA were assessed. Dofetilide was successfully started in 176 patients (81%) and had to be discontinued in the remaining 41 patients (19%). Dofetilide was initiated for control of ventricular tachycardia (VT) in 136 patients (77%), whereas 40 (23%) patients were initiated on dofetilide for reducing the burden of premature ventricular complexes (PVCs).

Results: The mean follow-up was 24 ± 7 months. In total, among the 136 VT patients, 33 (24%) died, 11 (8%) received a left ventricular assist device (LVAD), and 3 (2%) received a heart transplant during follow-up. Dofetilide was discontinued in 117 (86%) patients due to lack of sustained effectiveness during follow-up. Dofetilide use was associated with similar odds of the composite outcome of all-cause mortality/LVAD/heart transplant (OR: 0.97, 0.55-4.23) in patients with ischemic cardiomyopathy (ICM) compared to those with non-ischemic cardiomyopathy (NICM). Dofetilide did not reduce PVC burden during follow-up in the 40 patients with PVCs (mean baseline PVC burden: 15%, at 1-year follow-up: 14%).

Conclusions: Dofetilide use was less effective in reducing VA burden in our cohort of patients. Randomized controlled studies are needed to confirm our findings.

Keywords: Dofetilide; Premature ventricular complexes; Ventricular arrhythmia; Ventricular tachycardia.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Shantha G, Alyesh D, Ghanbari H, Oral H. Antiarrhythmic drug therapy and all-cause mortality after catheter ablation of atrial fibrillation: a propensity-matched analysis. Heart Rhythm. 2019;16:1368–73. - DOI - PubMed
    1. Mounsey JP, DiMarco JP. Cardiovascular drugs. Dofetilide. Circulation. 2000;102:2665–70. - DOI - PubMed
    1. Boriani G, Lubinski A, Capucci A, et al. A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease. Eur Heart J. 2001;22:2180–91. - DOI - PubMed
    1. Bashir Y, Thomsen PE, Kingma JH, et al. Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia Dofetilide Arrhythmia Study Group. Am J Cardiol. 1995;76:1040–4. - DOI - PubMed
    1. Baquero GA, Banchs JE, Depalma S, et al. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies. J Cardiovasc Electrophysiol. 2012;23:296–301. - DOI - PubMed

MeSH terms

LinkOut - more resources